ANTOLRX
  • Our Vision
  • Science
  • Pipeline
  • Team
  • News
  • Careers
Select Page

AnTolRx, Inc. Announces Series A Equity Funding from Pfizer, JDRF and Orion Equity Partners, LLC to Develop Targeted Nanoparticle Tolerance Therapeutics

by AnTolRx | Sep 8, 2016 | Press Release

CAMBRIDGE, Mass., September 8, 2016—AnTolRx, Inc. announced today that it has signed a Series A funding agreement with Pfizer Inc. (NYSE: PFE), Orion Equity Partners LLC and JDRF, the leading global organization funding type 1 diabetes (T1D) research. The funding...

News Archives

  • December 2020
  • February 2020
  • December 2019
  • November 2019
  • October 2019
  • March 2019
  • February 2019
  • January 2019
  • August 2018
  • April 2018
  • January 2018
  • November 2016
  • September 2016
  • August 2016

LOCATION

AnTolRx
One Kendall Square
Building 1400 West, Suite 14303
Cambridge, MA 02139

CONTACT

AnTolRx
info@antolrx.com
617-902-0601

  • Home
  • Our Vision
  • Science
  • Pipeline
  • News
  • Careers
  • Contact
© 2025 ANTOLRX | Website by &#10070OnyxWP